LONDON, UK / ACCESSWIRE / March 19, 2018 / Active-Investors.com has just released a free earnings report on Molina Healthcare, Inc. (NYSE: MOH) ("Molina"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MOH. The Company posted its financial results on February 12, 2018, for the fourth quarter of the fiscal year 2017 (Q4 FY17) and for the full fiscal year 2017 (FY17). The Company's quarterly total revenues grew on a y-o-y basis. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Molina Healthcare most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=MOH

Earnings Highlights and Summary

During the quarter ended December 31, 2017, Molina reported total revenues of $4.95 billion compared to $4.53 billion in Q4 FY16. However, the Company's total revenue numbers lagged market consensus estimates of $4.96 billion.

The provider of Medicaid-related services posted a net loss of $262 million, or $4.59 loss per diluted share, in Q4 FY17, up from a net loss of $47 million, or $0.85 loss per diluted share, in Q4 FY16. The Company's adjusted net loss came in at $258 million, or $4.52 loss per diluted share, in Q4 FY17 compared to a net loss of $42 million, or $0.75 loss per diluted share, in Q4 FY16.

In FY17, Molina's total revenues came in at $19.88 billion compared to $17.78 billion in FY16. The Company reported a net loss of $512 million, or $9.07 loss per diluted share, in FY17 versus a net income of $52 million, or $0.92 per diluted share, in FY16. Additionally, the Company's adjusted net loss stood at $493 million, or $8.72 loss per diluted share, in FY17 compared to an adjusted income $72 million, or $1.28 per diluted share, in FY16.

Operational Metrics

The Long Beach, California-based Company's total operating expenses increased to $5.22 billion during Q4 FY17 from $4.54 billion in the last year's same quarter. The Company posted an operating loss of $269 million in Q4 FY17 compared to an operating loss of $6 million in Q4 FY16. The Company reported negative earnings before interest, tax, depreciation, and amortization (EBITDA) of $247 million in Q4 FY17 versus positive EBITDA of $37 million in Q4 FY16.

Segment Results

Molina's Total Medicaid segment reported revenues of $3.51 billion in Q4 FY17 compared to $3.37 billion in Q4 FY16. The segment's total costs came in at $3.11 billion in Q4 FY17 versus $3.03 billion in the previous year's comparable quarter. Additionally, the segment's total medical margin grew to $401 million in Q4 FY17 from $339 million in Q4 FY16.

Molina's Total Medicare segment's revenues rose to $515 million in Q4 FY17 from $469 million in the previous year's corresponding quarter. The segment's total cost was $465 million in the reported quarter compared to $404 million in Q4 FY16. Furthermore, the segment reported a medical margin of $50 million in Q4 FY17 versus $65 million in Q4 FY16.

The Company's Marketplace segment's revenues improved to $665 million during Q4 FY17 from $349 million in Q4 FY16. The segment's total cost was $678 million in Q4 FY17 compared to $407 million in Q4 FY16.

Cash Flow and Balance Sheet

During Q4 FY17, the Company used $153 million in its operating activities compared to $40 million in the prior year's same quarter. At the close of books on December 31, 2017, Molina had $3.19 billion in cash and cash equivalents compared to $2.82 billion at the close of books on December 31, 2016. The Company's long-term debt stood at $1.32 billion as on December 31, 2017, compared to $975 million as on December 31, 2016.

Outlook for FY18

In its guidance for FY18, Molina's management expects total revenues to be approximately $18.8 billion. EBIDTA is anticipated to be between $632 million and $676 million. The Company forecasts adjusted diluted net income per share to be between $3.23 and $3.73.

Stock Performance Snapshot

March 16, 2018 - At Friday's closing bell, Molina Healthcare's stock advanced 1.27%, ending the trading session at $76.83.

Volume traded for the day: 1.61 million shares, which was above the 3-month average volume of 1.27 million shares.

Stock performance in the last month ? up 4.89%; previous three-month period ? up 2.32%; past twelve-month period ? up 70.13%; and year-to-date ? up 0.20%

After last Friday's close, Molina Healthcare's market cap was at $4.53 billion.

The stock is part of the Healthcare sector, categorized under the Health Care Plans industry. This sector was up 0.2% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors